Nabriva Therapeutics plc (NBRV) Misses Q3 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts NBRV Hot Sheet
Join SI Premium – FREE
Nabriva Therapeutics plc (NASDAQ: NBRV) reported Q3 EPS of ($4.21), $0.18 worse than the analyst estimate of ($4.03). Revenue for the quarter came in at $9.15 million versus the consensus estimate of $11.05 million.
For earnings history and earnings-related data on Nabriva Therapeutics plc (NBRV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- VisionChina (VISN) Tops Q3 EPS by 1c
- Vericel (VCEL) Tops Q3 EPS by 21c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
